Hypothermia Clinical Trial
Official title:
Intravenous Amino Acid Infusion in Mothers Before and During Cesarean Delivery: Effects on Maternal and Neonatal Temperature
Introduction: Intravenous infusion of amino acids during cesarean delivery in mothers and
neonates improves neonatal growth. Amino acid before and during anesthesia also prevents
hypothermia and associated untoward effects.
Method: After ethical approval, this prospective randomized double blind controlled study is
being conducted in the university hospital of BPKIHS. Seventy six parturients (ASA 1 & 2)
undergoing cesarean delivery without fetal distress, intrauterine growth retardation,
congenital malformation or premature labor will be enrolled.
For a period starting from approximately one hour prior to spinal anesthesia, Group 1 and
Group 2 patients will receive 200 ml of amino acid and lactated ringers solution respectively
at 2 ml/kg/hr. The ambient operating room temperature will be maintained near 23º C. No
heating methods will be applied apart from covering with a blanket.
Primary outcome measure will be neonatal rectal temperature at 0, 5 and 10 min after birth.
Secondary outcome measures will be APGAR scores and suckling reflex in the newborn, change in
rectal temperature relative to baseline and discomfort related to cold sensation in the
mother and the occurrence of shivering both in the mother and newborn.
Review of literature:
Hypothermia is common during peri-operative period (1). It can lead to shivering (2),
sympathetic stimulation (3), ischemic cardiac events (3), coagulation disturbances (4,5)
delayed recovery from anesthesia (6,7), altered immune system with impaired wound healing
(8,9) and prolonged hospitalization (9).
Amino acid infusion before and during surgery is known to prevent peri-operative hypothermia
as a result of increased thermogenesis (10,11) without additional sympatho-adrenal activity
(12). The mechanism is based on nutrient induced thermogenesis; i.e., nutrient intake,
especially proteins and amino acids, stimulates resting energy expenditure and heat
production (13). This effect is more pronounced during general anesthesia than neuraxial
block (14). It has also been proved that amino acid infusion before and/or during anesthesia
and surgery decreases intra-operative blood loss (15), improves peri-operative recovery (16)
and shortens the duration of hospital stay (17).
The safety of intravenous amino acid infusion during cesarean delivery was long ago
established (18,19).While maternal intravenous administration of amino-acids led to increased
levels of amino acids in maternal venous blood and fetal umbilical cord blood plasma, there
was no increase in fetal uptake of amino acids.
The safety of amino acid in the first day of life after delivery has also already been proved
(20,21). It has been used to achieve positive protein balance in the immediate postoperative
period in neonates undergoing abdominal surgery (20). Aggressive therapy of intravenous amino
acid in preterm infants during 12 hrs to two weeks after birth enhanced their growth and
improved their nutritional status during hospitalization (21).
Rationale of the study:
One way to prevent the development of hypothermia during anesthesia is to stimulate
endogenous heat production. Energy expenditure increases after ingestion or infusion of
nutrients. The amount of energy expended over baseline, or thermic effect of food mainly
represents the energy cost of nutrient absorption, handling, and storage. Among the different
nutrients, proteins elicit the largest increase in energy expenditure and heat production.
Previous studies have found that intravenous amino acid infusions exert enhanced thermogenic
effects during general anesthesia (10) The mechanism behind this phenomenon is not fully
understood, although nutrient intake stimulates energy expenditure, and hence heat
production, in the awake state (13). The administration of proteins/amino acids in awake
individuals results in an approximately 20% increase in whole-body heat content and a
significant increase in body temperature (22,23).
Since amino acid transfer across the placenta depends upon its concentration in maternal
blood (21,24), the investigators hypothesize that by increasing its concentration in the
maternal blood, the amino acid level in newborn will be increased. The amino acid induced
increased thermogenesis in the mother is likely to increase maternal temperature and thus
fetal temperature. Also amino acids that have crossed the placenta may increase thermogenesis
in the fetus, further enhancing neonatal temperature.
Research design and methodology:
After getting approval from the institutional research ethics committee and written informed
consent, this prospective randomized double blind study was conducted in the University
hospital of B P Koirala Institute of Health Sciences (BPKIHS). Parturients belonging to
American Society of Anesthesiologists physical status I and II scheduled for elective
cesarean delivery were enrolled. Pregnancy with fetal distress, intrauterine growth
retardation, congenital malformation or premature labor were excluded.
With the help of computer generated random numbers, each consecutive eligible patients
scheduled for cesarean delivery were assigned to one of the two groups to receive 200 ml of
intravenous amino acid (Active drug) (n=38) or nutrient free standard ringers lactate
solution (active comparator) (n=38) at 2 ml/kg/hr approximately one hour before spinal
anesthesia. Amino acid solution used was a balanced mixture of 18 pure crystalline amino
acids, eight of which are essential amino acids (Alamin SN ®, Albert D Limited, Kolkata,
India).
On the pre-anesthetic visit one day prior to surgery, all the patients were explained about
the nature of the study and the various questions to be asked during the study. Approximately
90 minutes prior to surgery, each patient was taken to the pre-operative room inside the
operation theater. Heart rate, respiratory rate, rectal temperature and SpO2 were monitored
continuously and non invasive blood pressure every five minutes. To maintain blinding, all
the infusion bags were covered with an opaque plastic sheet and labelled as 'infusion bag'
and hanged on the infusion stand near the patient by an anesthetist not involved in the
management or data collection thereafter. Intravenous infusion of amino acid solution or
ringer's solution was started approximately one hour prior to spinal anesthesia after
recording the baseline vital parameters. Each patient received a total of 200 ml at 2
ml/kg/min. Both the patients and the assessor were unaware of the group assignment.
After one hour of infusion, each patient was transferred to the operating room. The ambient
temperature of the operating room was maintained near 23°C. The monitoring of non invasive
blood pressure, heart rate, respiratory rate, oxygen saturation (SpO2) and rectal temperature
were continued at the same intervals. Spinal anesthesia was induced with 2 ml of 0.5%
bupivacaine at L 3-4 inter-space applying aseptic precautions with the patient in the lateral
position. After administration of spinal anesthesia, both groups received Ringers solution
15-20 ml/kg/hr maintained at ambient temperature via a separate venous access. All the
patients were covered with a blanket, but no other heating methods were applied. Amino acid
infusion were continued till the completion of 200 ml the solution contained in the infusion
bag.
The maternal rectal temperature were recorded before infusion (baseline), prior to spinal
block, at the time of delivery, at half an one hour after spinal block, and at the end of
infusion of 200 ml of study solution. At the end of surgery, each mother was asked about her
perception of cold and its related discomfort on a 0-2 subjective scale (0= No perception, 1=
Tolerable perception, 2=Intolerable perception).
The rectal temperature and APGAR scores were assessed at 0, 5 and 10 minutes and suckling
reflex at 10 minutes of the birth of baby. The occurrence of shivering and duration of
hospital stay were noted for both the mother and baby.
Primary outcome parameters was the neonatal rectal temperature at 0, 5 and 10 minutes after
birth. Secondary outcome parameters included neonatal APGAR scores at 0, 5 and 10 minutes
after birth, the number of newborn having suckling reflex; number of neonates who developed
shivering within 10 minutes after birth; change in maternal rectal temperature relative to
baseline at various time points during study drug infusion, maternal temperature at the time
of delivery during intraoperative period; number of mothers developing cold sensation related
discomfort during the intra-operative period; number of mothers who developed shivering
during intra-operative period.
Previous report showed that the mean rectal temperature of new born immediately after
delivery following spinal anaesthesia was 37.7°C. (22) With the help of STATA, it was
estimated that a sample size of 26 in each group could achieve a power of 95% to detect a
difference of 0.5 °C (with common standard deviation of 0.5) in the outcome measure of new
born rectal temperature, assuming type 1 error of 0.05.
For the secondary outcome, the sample size was calculated using online statistical calculator
G power (R) version 3.0.1. Cohen d was used to calculate the effect size based on the
findings of a previous study.(14) The mean final core temperature 90 min after induction of
spinal anaesthesia was 35.8 (SEM 0.1)°C in the saline group and 36.6 (0.1)°C in the amino
acid group.(14) It was estimated that a sample size of 34 in each group could achieve a power
of 80% to detect an effect size of 0.69 in the outcome measure of maternal core body
temperature, assuming type 1 error of 0.05. We enrolled 38 patients in each group to
compensate for dropout cases and shifting from normality in data distribution.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05669313 -
The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
|
||
Not yet recruiting |
NCT05306392 -
Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT02685176 -
Head and Torso Rewarming Using a Human Model for Severe Hypothermia
|
N/A | |
Completed |
NCT02586974 -
Effects of Warmed, Humidified CO2 Insufflation on Body Core Temperature and Cytokine Response
|
N/A | |
Withdrawn |
NCT02812069 -
WarmSmart Warming Protocol
|
N/A | |
Not yet recruiting |
NCT02211703 -
National Epidemiologic Survey on the Incidence of Perioperative Hypothermia
|
N/A | |
Completed |
NCT02177903 -
Study to Determine the Effects of Pre-warming on OR Patient Temperatures and Surgical Outcomes
|
N/A | |
Completed |
NCT02742818 -
Forced-air Warming in Endovascular Surgery: Testing Effectiveness of Two Different Blanket Models
|
N/A | |
Completed |
NCT02121574 -
Accuracy of Zero-flux and Ingestible Thermometers
|
N/A | |
Recruiting |
NCT01866384 -
Targeted Temperature Management After Intracerebral Hemorrhage
|
Phase 2 | |
Active, not recruiting |
NCT01529658 -
Renal Hypothermia During Partial Nephrectomy
|
N/A | |
Completed |
NCT01722955 -
Pre-warmed Intravenous Fluids and Monitored Anesthesia Care
|
N/A | |
Completed |
NCT01793337 -
Core Body Temperature Measurement During Hot and Cold Environmental Exposure
|
N/A | |
Completed |
NCT01559675 -
Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery
|
N/A | |
Terminated |
NCT01018576 -
Delayed Cord Clamping in Premature Infants
|
N/A | |
Terminated |
NCT00822796 -
Thermogard™ Efficacy Trial
|
N/A | |
Completed |
NCT00904228 -
Plastic Hat Trial to Prevent Hypothermia in Preterm Newborns in the Delivery Room
|
N/A | |
Completed |
NCT00334360 -
Dexmed/Buspirone Synergism on Shivering
|
Phase 4 | |
Not yet recruiting |
NCT06283771 -
The Effect of Heated Socks Developed With Wearable Technology on Hypothermia, Thermal Comfort Perception and Shivering
|
N/A | |
Completed |
NCT04399902 -
Study to Actively Warm Trauma Patients
|
N/A |